Table 4.
Gene mutation analysis of TETs from previously published literature.
| Case | Author | Year | Type | N0 | Mutation | Sequencing Method | Country |
|---|---|---|---|---|---|---|---|
| 1 | Chen et al. (26) | 2020 | Thymoma | 50 | MAP3K1 (98%), TGFBR2 (96%), KMT2C (94%), ARID1A (92%), PRKDC (90%) | Next-generation sequencing for 315 genes | China |
| Thymic carcinoma | 5 | ARID1A (100%), KMT2C (100%), MAP3K1 (100%) | |||||
| 2 | Thompson et al. (27) | 2020 | Thymoma | 3 | HRAS (33.3%) | Next-generation sequencing for 1385 genes | USA |
| 3 | Sakane et al. (28) | 2019 | Thymoma | 33 | HRAS (3.0%); PIK3CA (6.1%); AKT1 (3.0%) | Single-base extension multiplex assay | Japan |
| Thymic carcinoma | 54 | KRAS (11.1%); HRAS (5.6%); TP53 (9.3%); EGFR (3.7%); PIK3CA (1.9%); NRAS (1.9%); AKT1 (1.9%) |
|||||
| 4 | Enkner et al. (29) | 2017 | Type A thymoma | 18 | HRAS (16.7%) | Next-generation sequencing for 50 genes | Austria |
| Type B3 thymoma | 19 | SMARCB (5.3%); STK11 (5.3%) | |||||
| Thymic carcinoma | 35 | TP53 (25.7%); CDKN2A (11.4%); FGFR3 (5.7%); KIT (5.7%); ALK (2.9%); ATM (2.9%); ERBB4 (2.9%); NRAS (2.9%); |
|||||
| 5 | Saito et al. (30) | 2017 | Thymic carcinoma | 10 | TET2 (30%); CACNA1A (30%); HTT (20%); MYNN (20%); OR5T2 (20%); ARID1B (20%); CYLD (20%); SETD2 (20%); |
Whole exome sequencing | Japan |
| 6 | Asao et al. (31) | 2016 | Thymic carcinoma | 52 | TP53 (7.7%), KRAS (3.8%), FBXW7 (3.8%), NRAS (1.9%), | Next-generation sequencing for 50 genes | Japan |
| 7 | Song et al. (32) | 2016 | Thymoma | 37 | EGFR (2.7%), PIK3CA (2.7%); | Next-generation sequencing for 22 genes | China |
| Thymic carcinoma | 15 | PIK3CA (6.7%) | |||||
| 8 | Moreira et al. (25) | 2015 | Type B3 thymoma | 6 | BCOR (50%); MLL3 (16.7%) | Next generation sequencing | USA |
| Thymic carcinoma | 15 | TP53 (26.7%), SMAD4 (13.3%), and CYLD (13.3%), KDM6A (20%), SETD2 (13.3%), MLL3 (13.3%), MLL2 (13.3%). | |||||
| 9 | Petrini et al. (33) | 2014 | Thymoma | 38 | GTF2I (42.1%); TP53 (5.3%); ALK (5.3%); PPP2RIA (5.3%) | Exome sequencing or 197-gene assay | USA |
| Thymic carcinoma | 16 | TP53 (25%); CYLD (18.8%); BAP (12.5%); PBRM (12.5%); CDKN2A (12.5%) |
|||||
| 10 | Shitara et al. (34) | 2014 | Thymic carcinoma | 12 | NF1 (16.7%); 8.3% for HRAS, PBRM1, DDR2, ASXL1, CDK8, CDKN2A, DCC, IGF1R, IKBKE, KAT6B, KDM6A, KIT, KMT2A, KMT2D, NKX2-1, PAX5, PDGFRA, PKHD1, ROS1, RUNX1T1, SMARCA4, TET1, TP53; | Ion Torrent next-generation sequencing for 409 cancer-related genes | Japan |
| 11 | Wang et al. (30) | 2014 | Thymoma | 31 | 3.2% for ASXL1, DCC, EGFR, ERG, HRAS, MAGI1, PDGFRA, PRCC, PTGS2, RUNX1, SDHA, SETD2, SRC, TET2, TP53 | Massively parallel sequencing of 197 cancer-related genes. | USA |
| Thymic carcinoma | 47 | TP53 (25.5%); BAP1 (10.6%); CYLD (8.5%); KIT (8.5%); DNMT3A (8.5%); SETD2 (8.5%); TET3 (6.4%); 4.3% for ASXL1, BRCA2, CDKN2A, DCC, SMARCA4 and WT1. | |||||
| 12 | Girard et al. (35) | 2009 | Thymoma | 38 | KRAS (2.6%); HRAS (2.6%) | Array-based comparative genomic hybridization. | USA |
| Thymic carcinoma | 7 | KIT (28.6%); KRAS (14.3%) | |||||
| 13 | Asselta et al. (36) | 2021 | Thymic carcinoma | 15 | FGFR3(33.3%);CDKN2A(20%);SMARCB1(13.3%); 6.6% for ATM, NRAS, SRC, APC, KIT, MET | Next-generation sequencing for 50 genes | Italy |
| 14 | Massoth et al. (37) | 2020 | Thymoma | 242 | KMT2A-MAML2 Fusion (4%) | Next-generation sequencing | USA |
| 15 | Sakane et al. (38) | 2021 | Thymic carcinoma | 54 | TP53 (18.5%), KIT (7.4%), and PDGFRA (5.6%) | Next-generation sequencing for 50 genes | Japan |